ASH Preview: J&J And Legend’s CAR-T Takes Center Stage

Frontrunners Bide Their Time

While bluebird bio, Celgene and GSK prepare to file, it’s time to shine for another myeloma contender.

As 2019 nears its end, there are several major congresses remaining, not least the year’s biggest blood disorders meeting, the American Society of Hematology (ASH).

The congress takes place in Orlando, Florida 7-10 December, and abstracts released on 6 November will highlight a huge breadth...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.